DE69221168T2 - Transfektion von vertebratenzellen beispielsweise durch homologe rekombination - Google Patents
Transfektion von vertebratenzellen beispielsweise durch homologe rekombinationInfo
- Publication number
- DE69221168T2 DE69221168T2 DE69221168T DE69221168T DE69221168T2 DE 69221168 T2 DE69221168 T2 DE 69221168T2 DE 69221168 T DE69221168 T DE 69221168T DE 69221168 T DE69221168 T DE 69221168T DE 69221168 T2 DE69221168 T2 DE 69221168T2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- product
- transfected
- primary
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78784091A | 1991-11-05 | 1991-11-05 | |
US78918891A | 1991-11-05 | 1991-11-05 | |
US91153392A | 1992-07-10 | 1992-07-10 | |
PCT/US1992/009627 WO1993009222A2 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69221168D1 DE69221168D1 (de) | 1997-09-04 |
DE69221168T2 true DE69221168T2 (de) | 1998-02-26 |
Family
ID=27419842
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232728T Expired - Fee Related DE69232728T2 (de) | 1991-11-05 | 1992-11-05 | DNA-Konstrukte und ihre Verwendung zur Transfektion von Zellen durch homologe Rekombination |
DE69221168T Revoked DE69221168T2 (de) | 1991-11-05 | 1992-11-05 | Transfektion von vertebratenzellen beispielsweise durch homologe rekombination |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232728T Expired - Fee Related DE69232728T2 (de) | 1991-11-05 | 1992-11-05 | DNA-Konstrukte und ihre Verwendung zur Transfektion von Zellen durch homologe Rekombination |
Country Status (19)
Country | Link |
---|---|
US (7) | US5994127A (de) |
EP (3) | EP1221477A3 (de) |
JP (3) | JP3564126B2 (de) |
KR (1) | KR100339316B1 (de) |
AT (2) | ATE155810T1 (de) |
AU (1) | AU669499B2 (de) |
CA (1) | CA2122991A1 (de) |
DE (2) | DE69232728T2 (de) |
DK (2) | DK0750044T3 (de) |
ES (2) | ES2181841T3 (de) |
GR (1) | GR3025054T3 (de) |
HK (1) | HK1014033A1 (de) |
IL (1) | IL103649A0 (de) |
MX (1) | MX9206376A (de) |
MY (1) | MY119132A (de) |
NZ (1) | NZ245015A (de) |
PT (1) | PT101031B (de) |
SG (1) | SG44652A1 (de) |
WO (1) | WO1993009222A2 (de) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US7094400B1 (en) * | 1987-05-01 | 2006-08-22 | Shire Human Genetic Therapies, Inc. | Transkaryotic implantation |
US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
ES2090297T5 (es) * | 1989-11-06 | 2005-03-01 | Cell Genesys, Inc. | Produccion de proteinas que utilizan recombinacion homologa. |
EP0779362B2 (de) | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
PT101031B (pt) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
EP1403376A3 (de) | 1993-04-21 | 2007-08-29 | The University Court Of The University Of Edinburgh | Exprimierung von heterologischen Genen mit einem gezielten Expressionprofil |
SE9402642D0 (sv) * | 1994-08-05 | 1994-08-05 | Maria Anvret | Gene Therapy |
US5965125A (en) | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
JP2001503963A (ja) * | 1996-02-06 | 2001-03-27 | イーライ・リリー・アンド・カンパニー | 糖尿病治療 |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
EP0935651B1 (de) | 1996-09-13 | 2004-12-29 | Transkaryotic Therapies, Inc. | THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ |
JP3869092B2 (ja) | 1996-10-01 | 2007-01-17 | ジェロン・コーポレーション | ヒトテロメラーゼ触媒性サブユニット |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
WO1998041645A1 (en) | 1997-03-14 | 1998-09-24 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
ES2273434T3 (es) * | 1997-07-23 | 2007-05-01 | Roche Diagnostics Gmbh | Obtencion de la eritropoyetina mediante activacion genica endogena. |
PT1000154E (pt) | 1997-07-23 | 2007-03-30 | Roche Diagnostics Gmbh | Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
DK1000154T3 (da) * | 1997-07-23 | 2007-06-18 | Roche Diagnostics Gmbh | Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6740503B1 (en) | 1997-09-26 | 2004-05-25 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
ZA989497B (en) † | 1997-10-20 | 2000-04-19 | Roche Diagnostics Gmbh | Positive-negative selection in homologous recombination. |
BR9813391C1 (pt) | 1997-12-03 | 2021-05-25 | Roche Diagnostics Gmbh | processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
ATE286127T1 (de) * | 1998-04-24 | 2005-01-15 | Transkaryotic Therapies Inc | Verabreichung der therapeutischen proteine durch implantation der genetischen modifizierten zellen in das omentum |
US6537806B1 (en) * | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
AU760619B2 (en) * | 1998-06-26 | 2003-05-22 | Genetronics, Inc. | Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent |
US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
EP1102608A4 (de) | 1998-07-13 | 2008-09-17 | Genetronics Inc | Methode und gerät zur elektrisch unterstützten oberflächlichen auftragung von kosmetikmitteln |
EP1100579B1 (de) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Auf haut und muskel gerrichtete gentherapie durch ein pulsierendes elektrisches feld |
AU766693B2 (en) * | 1998-11-24 | 2003-10-23 | Emory University | Transgenic circulating endothelial cells |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
WO2000065027A2 (en) | 1999-04-28 | 2000-11-02 | Genetics Institute, Inc. | Human gil-19/ae289 proteins and polynucleotides encoding same |
ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
ATE412670T1 (de) | 1999-09-29 | 2008-11-15 | Gen Hospital Corp | Parathyroid hormon (pth) polypeptidderivate |
US7229793B1 (en) | 1999-11-19 | 2007-06-12 | Shire Human Genetic Therapies, Inc. | Constructs and cells for production of small peptides |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
WO2001042442A2 (en) | 1999-12-10 | 2001-06-14 | Cytos Biotechnology Ag | Activation of endogenous genes by genomic introduction of a replicon |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
EP1728862A1 (de) | 2000-03-16 | 2006-12-06 | Genetica, Inc. | Methoden und Zusammensetzungen zur Interferenz durch RNA |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
CA2747325A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
KR100407792B1 (ko) * | 2000-08-02 | 2003-12-01 | 한국생명공학연구원 | 인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법 |
DE60134251D1 (de) | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
CA2441071C (en) | 2001-03-14 | 2010-06-22 | Myriad Genetics, Inc. | Tsg101-gag interaction and use thereof |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
US20030143191A1 (en) * | 2001-05-25 | 2003-07-31 | Adam Bell | Chemokine beta-1 fusion proteins |
CA2451317C (en) | 2001-06-26 | 2016-03-29 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
IL159640A0 (en) | 2001-07-10 | 2004-06-01 | Senomyx Inc | Use of specific t2r taste receptors to identify compounds that block bitter taste |
CN1363654A (zh) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法 |
EP1554572B1 (de) * | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
WO2003043674A1 (en) * | 2001-11-16 | 2003-05-30 | Children's Medical Center Corporation ¨ | Augmentation of organ function |
EP1463752A4 (de) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albuminfusionsproteine |
EP1463751B1 (de) * | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albuminfusionsproteine |
EP1468099A2 (de) * | 2002-01-17 | 2004-10-20 | Lonza Biologics plc | Zur produktion von proteinen und zum wachstum in einem glutaminfreien medium fähige glutaminauxotrophe menschliche zellen |
US7772459B2 (en) | 2002-02-20 | 2010-08-10 | Bellweather Farms | Transgenic production in saliva |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
JP5570677B2 (ja) | 2002-04-25 | 2014-08-13 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼA欠損症の治療 |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
JP2006517101A (ja) * | 2003-01-13 | 2006-07-20 | エス. ラオ、マヘンドラ | 治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現 |
EP1594433B8 (de) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Sensibilisator für krebstherapie |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
NZ545747A (en) | 2003-08-06 | 2010-06-25 | Senomyx Inc | T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
CN1901934B (zh) * | 2003-12-19 | 2013-09-11 | 弗·哈夫曼-拉罗切有限公司 | 促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途 |
WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
US7893034B2 (en) | 2004-09-02 | 2011-02-22 | Yale University | Regulation of oncogenes by microRNAs |
EP1896083B1 (de) | 2005-05-17 | 2016-03-02 | Amicus Therapeutics, Inc. | Verfahren zur behandlung von pompe-krankheit mit 1-desoxynojirimycin und derivaten |
US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
AU2006287315B2 (en) | 2005-09-09 | 2013-02-21 | The Johns Hopkins University | Manipulation of regulatory T cell and DC function by targeting neuritin gene using antibodies, agonists and antagonists |
MX2007015931A (es) | 2005-10-20 | 2008-04-22 | Senomyx Inc | Receptores de sabor dulce-umami y umami-dulce humanos quimericos. |
JP2009514535A (ja) | 2005-11-03 | 2009-04-09 | レッドポイント バイオ コーポレイション | Trpm5イオンチャネルのためのハイスループットスクリーニングアッセイ |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
KR101387563B1 (ko) | 2006-04-21 | 2014-04-25 | 세노믹스, 인코포레이티드 | 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법 |
JP2007325571A (ja) * | 2006-06-09 | 2007-12-20 | Toto Ltd | 組換え哺乳類動物細胞を用いたタンパク質生産方法 |
EP2377953A1 (de) | 2006-06-23 | 2011-10-19 | Myriad Genetics, Inc. | Varianten des DPYD-Gens und ihre Verwendung |
US7674594B2 (en) | 2006-07-27 | 2010-03-09 | Redpoint Bio Corporation | Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol |
EP2120998B1 (de) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung |
EA200971050A1 (ru) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |
CN101687009A (zh) | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | 治疗皮肤溃疡的方法 |
US9580688B2 (en) * | 2007-06-08 | 2017-02-28 | Wake Forest University Health Sciences | Kidney structures and methods of forming the same |
JP2010528658A (ja) | 2007-06-08 | 2010-08-26 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 腎不全の治療のための選択的細胞治療 |
EP2006388A1 (de) * | 2007-06-19 | 2008-12-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | Nukleinsäurekonstrukte zur Inaktivierung und konditionalen Mutagenese von Genen |
CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
CL2008002054A1 (es) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
MX346714B (es) | 2007-08-01 | 2017-03-24 | The General Hospital Corp * | Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas. |
EP3176263A1 (de) * | 2007-08-10 | 2017-06-07 | Toto Ltd. | Verfahren zur herstellung von rekombinanten säugerzellen |
EP2195656A4 (de) | 2007-08-21 | 2011-10-19 | Senomyx Inc | Menschliche t2r-bitterkeit-rezeptoren und verwendungen davon |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
EP3219795B1 (de) | 2008-01-18 | 2024-03-13 | BioMarin Pharmaceutical Inc. | Herstellung von aktiven hoch phosphorylierten humanen lysosomalen sulfataseenzymen und verwendungen davon |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
AU2009296397B2 (en) | 2008-09-26 | 2012-11-08 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
WO2010037224A1 (en) | 2008-10-03 | 2010-04-08 | St. Michael's Hospital | Method for preventing and treating cardiovascular diseases with brca1 |
KR20220112862A (ko) | 2008-11-12 | 2022-08-11 | 인리젠 | 분리된 신장 세포 및 이의 용도 |
WO2010057013A1 (en) * | 2008-11-14 | 2010-05-20 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
US20100178641A1 (en) * | 2009-01-12 | 2010-07-15 | Franklin David Damon | Apparel fastening learning apparatus |
US8211655B2 (en) | 2009-02-12 | 2012-07-03 | Discoverx Corporation | Wild-type receptor assays |
EP2451475A2 (de) | 2009-07-06 | 2012-05-16 | Novartis AG | Selbstreplizierende rna-moleküle und ihre verwendung |
CA2775012A1 (en) | 2009-09-23 | 2011-03-31 | Biogenerix Ag | Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same |
US9492508B2 (en) | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
AR082319A1 (es) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
WO2012035037A1 (en) | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
AU2011326767B2 (en) | 2010-11-10 | 2016-02-11 | Prokidney | Injectable formulations for organ augmentation |
CN103328038A (zh) | 2010-12-01 | 2013-09-25 | 史拜诺莫度雷森公司 | 向神经解剖结构直接递送药剂 |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
CA2844197A1 (en) | 2011-08-03 | 2013-02-07 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System | Treatment of fibrosis using microrna-19b |
EP2869842A1 (de) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogene zusammensetzungen und verwendungen davon |
WO2014138921A1 (en) | 2013-03-15 | 2014-09-18 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
BR112016002622B1 (pt) | 2013-08-20 | 2023-04-11 | Lek Pharmaceuticals D.D | Meio de cultura celular e uso de selênio |
JP6841753B2 (ja) | 2014-09-15 | 2021-03-10 | ザ チルドレンズ メディカル センター コーポレーション | ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物 |
MA40871A (fr) | 2014-10-29 | 2017-09-05 | Novartis Ag | Expression directe d'anticorps |
CA3027143A1 (en) | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
ES2909454T3 (es) | 2017-12-29 | 2022-05-06 | Hoffmann La Roche | Procedimiento para proporcionar una composición de proteína PEGilada |
SI3731872T1 (sl) | 2017-12-29 | 2022-04-29 | F. Hoffmann-La Roche Ag | Postopek za zagotavljanje sestavka PEGiliranih beljakovin |
SG11202005990RA (en) | 2017-12-29 | 2020-07-29 | Hoffmann La Roche | Process for providing pegylated protein composition |
WO2021177387A1 (ja) * | 2020-03-04 | 2021-09-10 | 株式会社メトセラ | エリスロポエチン産生能が亢進された線維芽細胞 |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396601A (en) * | 1980-03-26 | 1983-08-02 | The Regents Of The University Of Calif. | Gene transfer in intact mammals |
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
EP0038765B1 (de) * | 1980-04-22 | 1987-09-02 | Institut Pasteur | Impfstoff gegen Hepatitis B Virus, Verfahren und transformierte eukaryotische Zellen zur Herstellung dieses Impfstoffes |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4680174A (en) * | 1984-05-24 | 1987-07-14 | Damon Biotech, Inc. | Induction of immune response by immunization with encapsulated antigen-producing cells |
CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
DE3688418T2 (de) * | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
DE3681787D1 (de) * | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3789678T2 (de) * | 1986-02-27 | 1994-08-11 | Snow Brand Milk Products Co Ltd | Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen. |
US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
DK173067B1 (da) * | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
GB8615942D0 (en) * | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5175255A (en) * | 1987-03-23 | 1992-12-29 | Amgen Inc. | Methods for purification of platelet-derived growth factor |
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
ES2094720T3 (es) * | 1987-05-01 | 1997-02-01 | Gen Hospital Corp | Implantacion transcariotica. |
US5166059A (en) * | 1987-06-16 | 1992-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy using gene fusions for genetic or acquired disorders |
AU613063B2 (en) * | 1987-07-06 | 1991-07-25 | Komatsu Zenoah Kabushiki Kaisha | Fuel supply system |
GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
JP3015383B2 (ja) * | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
JP2914692B2 (ja) * | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
US4890286A (en) * | 1987-12-11 | 1989-12-26 | Sanyo Electric Co., Ltd. | Method and apparatus for decoding error correcting code |
DE3802640A1 (de) * | 1988-01-29 | 1989-08-03 | Roehm Gmbh | Haarerhaltendes aescherverfahren |
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
JPH04507041A (ja) * | 1988-12-13 | 1992-12-10 | アメリカ合衆国 | 遺伝工学により修飾された内皮細胞およびその利用方法 |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
GB8907700D0 (en) * | 1989-04-05 | 1989-05-17 | Fine Organics Ltd | Preparation of substituted ethenes |
GB8909218D0 (en) * | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
CA2058955A1 (en) * | 1989-06-13 | 1990-12-14 | Helen Blau | Isolation growth and differentiation of human muscle cells |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
ES2090297T5 (es) * | 1989-11-06 | 2005-03-01 | Cell Genesys, Inc. | Produccion de proteinas que utilizan recombinacion homologa. |
EP0779362B2 (de) * | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
HUT60523A (en) * | 1990-02-22 | 1992-09-28 | Biogen Inc | Improved process for expressing polypeptides |
IT1241123B (it) * | 1990-04-19 | 1993-12-29 | Consiglio Nazionale Ricerche | Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego |
CA2084774A1 (en) * | 1990-06-12 | 1991-12-13 | Allan Bradley | Method for homologous recombination in animal and plant cells |
AU664976B2 (en) * | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
WO1992007573A1 (en) * | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
CA2096222C (en) * | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
CA2076848A1 (en) * | 1990-12-26 | 1992-06-27 | Richard C. Mulligan | Modified hepatocytes and uses therefor |
WO1992015676A1 (en) * | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Somatic cell gene therapy |
SG93780A1 (en) * | 1991-05-06 | 2003-01-21 | Cell Genesys Inc | Gene manipulation and expression using genomic elements |
EP0539573A4 (en) * | 1991-05-15 | 1993-12-29 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
AU2515992A (en) * | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
PT101031B (pt) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
US6531124B1 (en) * | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
US6670178B1 (en) * | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
KR960037062A (ko) * | 1996-08-02 | 1996-11-19 | 오동덕 | 화농성 피부질환 치료제의 제조방법 |
-
1992
- 1992-11-04 PT PT101031A patent/PT101031B/pt not_active IP Right Cessation
- 1992-11-04 NZ NZ245015A patent/NZ245015A/en not_active IP Right Cessation
- 1992-11-05 ES ES96202037T patent/ES2181841T3/es not_active Expired - Lifetime
- 1992-11-05 AT AT92924367T patent/ATE155810T1/de not_active IP Right Cessation
- 1992-11-05 EP EP01204619A patent/EP1221477A3/de not_active Withdrawn
- 1992-11-05 SG SG1996005101A patent/SG44652A1/en unknown
- 1992-11-05 AU AU30698/92A patent/AU669499B2/en not_active Ceased
- 1992-11-05 MY MYPI92002007A patent/MY119132A/en unknown
- 1992-11-05 WO PCT/US1992/009627 patent/WO1993009222A2/en not_active Application Discontinuation
- 1992-11-05 MX MX9206376A patent/MX9206376A/es active IP Right Grant
- 1992-11-05 EP EP92924367A patent/EP0649464B1/de not_active Revoked
- 1992-11-05 DK DK96202037T patent/DK0750044T3/da active
- 1992-11-05 IL IL103649A patent/IL103649A0/xx not_active IP Right Cessation
- 1992-11-05 EP EP96202037A patent/EP0750044B1/de not_active Expired - Lifetime
- 1992-11-05 ES ES92924367T patent/ES2106891T3/es not_active Expired - Lifetime
- 1992-11-05 DK DK92924367.3T patent/DK0649464T3/da active
- 1992-11-05 CA CA002122991A patent/CA2122991A1/en not_active Abandoned
- 1992-11-05 DE DE69232728T patent/DE69232728T2/de not_active Expired - Fee Related
- 1992-11-05 DE DE69221168T patent/DE69221168T2/de not_active Revoked
- 1992-11-05 AT AT96202037T patent/ATE221917T1/de not_active IP Right Cessation
- 1992-11-05 JP JP50876793A patent/JP3564126B2/ja not_active Expired - Fee Related
-
1994
- 1994-05-04 KR KR10-1994-0701527A patent/KR100339316B1/ko not_active IP Right Cessation
- 1994-11-04 US US08/334,455 patent/US5994127A/en not_active Expired - Lifetime
-
1995
- 1995-05-22 US US08/446,911 patent/US6048724A/en not_active Expired - Lifetime
- 1995-05-22 US US08/446,909 patent/US6048524A/en not_active Expired - Lifetime
-
1997
- 1997-10-15 GR GR970402700T patent/GR3025054T3/el unknown
-
1998
- 1998-12-24 HK HK98115412A patent/HK1014033A1/xx not_active IP Right Cessation
-
1999
- 1999-06-08 US US09/328,130 patent/US6846676B2/en not_active Expired - Fee Related
- 1999-10-19 US US09/420,861 patent/US6355241B1/en not_active Expired - Lifetime
-
2002
- 2002-12-11 JP JP2002359926A patent/JP3733110B2/ja not_active Expired - Fee Related
-
2004
- 2004-07-07 US US10/885,899 patent/US7410799B2/en not_active Expired - Lifetime
- 2004-07-22 JP JP2004214021A patent/JP2005046147A/ja active Pending
-
2008
- 2008-06-24 US US12/145,324 patent/US20100143314A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69221168D1 (de) | Transfektion von vertebratenzellen beispielsweise durch homologe rekombination | |
MY140230A (en) | Activating expression of an amplifying endogenous gene by homologous recombination | |
US5354674A (en) | Method of gene transfer using retrotransposons | |
CN101622353B (zh) | 蛋白生产的改良 | |
MX9605542A (es) | Produccion de proteinas y liberacion de proteinas. | |
NL930127I1 (nl) | Vorming van een meervoudig werkzame granulocytkolonie-stimulerende factor | |
DE69927707T2 (de) | Menschliche hybrid-wirtszelle zur expression von säugetier-genen | |
Cervera et al. | Extended gene expression by medium exchange and repeated transient transfection for recombinant protein production enhancement | |
CA2321964A1 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus | |
CN104342454A (zh) | 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用 | |
US20110008894A1 (en) | Lyophilized plasmid/dna transfection reagent carrier complex | |
Li et al. | Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines | |
EP2933331A1 (de) | Expressionskassette | |
Lampela et al. | Efficient transfection of novel bovine papillomavirus 1 expression plasmids | |
Monaco | Optimizing gene expression in mammalian cells | |
Moreau-Toussaint et al. | Efficient mRNA Delivery in difficult-to-transfect cells with jetMESSENGER® Transfection Reagent | |
Gonos | Organization and In Vitro Expression of Human tRNA Glu Genes | |
Chau et al. | Gene transfer into retinoblastoma cells | |
CN111500637A (zh) | 一种提高细胞脂质体转染效率的方法 | |
CN117106065A (zh) | 一种调控hbb液-液相分离能力和功能的方法 | |
Oberbek et al. | Lentiviral vectors for rapid and efficient recombinant CHO cell line generation | |
CN103509754A (zh) | Hiv-1 ltr上顺式元件突变的真核细胞系统及其制备方法与应用 | |
Le Blay et al. | Efficient transient gene expression in neurosphere with jetMESSENGER™ mRNA Transfection Reagent | |
Kim et al. | Translation and fates of the gag protein of 1731, a Drosophila melanogaster retrotransposon | |
Diamond | DEVELOPMENT OF AN IN VITRO SYSTEM FOR STUDYING DNA RECOMBINATION IN MAMMALIAN CELLS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |